You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.

ABOUT JAMA
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In

Vol. 243 No. 17, May 2, 1980 TABLE OF CONTENTS
  JAMA
 •  Online Features
ARTICLE
 This Article
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Contact me when this article is cited
 Related Content
 •Similar articles in JAMA

Chemotherapy for advanced male breast cancer

H. Y. Yap, C. K. Tashima, G. R. Blumenschein, G. N. Hortobagyi and N. Eckles

An analysis of 29 chemotherapeutic trials in 18 male patients with advanced breast cancer disclosed an overall response rate of 44%. Most of these chemotherapeutic trials consisted of single-agent regimens, namely, fluorouracil, methotrexate, thiotepa, cyclophosphamide, and melphalan. Our data suggest that responsiveness of advanced male breast cancer to systemic chemotherapeutic agents is the same as that reported for advanced female breast cancer.




HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 1980 American Medical Association. All Rights Reserved.